Rashid K. Sayyid, Urology Resident in the Department of Surgery at Augusta University, shared a post on X:
“COSMIC-313: Final results.
Ipi + Nivo +/- Cabo in aRCC pts (n=885, f/u: 45 mo):
- PFS benefit: 16.6 vs 11.2 mo (limited to IMDC int risk only: 22.1 vs 11.3 mo; poor risk: 9.5 vs 11.2 mo).
- No OS benefit in overall, int or poor risk groups.
- Triplet combo not well tolerated (only 50% tolerated all 4 cycles of Ipi).
- RNA seq data Tumors w/ M2-like macrophages benefited most from cabo addition to ipi + nivo.”
